ClinicalTrials.gg
CompletedNCT06928779Updated Apr 15, 2025

Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant

A Phase 1 interventional study of Dazucorilant in Hepatic Impairment, sponsored by Corcept Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-15.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.
  • Registered 6 months after the study started (first participant enrolled Oct 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study will compare the pharmacokinetics (PK) of dazucorilant (CORT113176) between participants with normal hepatic function and participants with hepatic impairment.

Read the detailed description

Initially, participants with moderate hepatic impairment and healthy control participants matched as to gender, age, and weight will be enrolled. After completing screening assessments, participants will receive a single dose of dazucorilant followed by an observation period of 7 days. Based on the observed effect of moderate hepatic impairment on the dazucorilant PK profile, and review of safety data, a group of participants with mild hepatic impairment, matched to the enrolled healthy control participants, may be enrolled to evaluate the effects of mild hepatic impairment on dazucorilant PK.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A non-smoker (no use of tobacco or nicotine products within 3 months prior to Screening) or light smokers (no more than 5 cigarettes/day or nicotine equivalent)
  • Has (BMI) ≥18.0 and ≤32 kg/m\^2 and body weight ≥50.0 kg
  • Female participants (except for and surgically sterile women) who are sexually active with a non-sterile male partner must be willing to use 1 of the acceptable methods described in the protocol throughout the study and for 90 days after study drug administration
  • Female participants of non- must be post-menopausal or surgically sterile
  • Male participants who are not vasectomized at least 6 months prior to study drug administration and who are sexually active with a non-sterile female partner must be willing to use 1 of the acceptable contraceptive methods described in the protocol from dosing until at least 90 days after study drug administration
  • Male participants must be willing not to donate sperm until 90 days following the administration of the study drug
  • Has estimated ≥60 mL/min/1.73 m\^2 at Screening
  • Is able to understand the study procedures, agree to abide by the study restrictions, and provide signed to participate in the study.

Additional Inclusion Criteria for Healthy Control Group Participants Only:

  • Healthy as defined by: a) on a population basis, matched to participants with moderate hepatic impairment according to gender, age (±10 years), and weight (±20%); b) BMI ≥18.0 and ≤32 kg/m\^2; c) the absence of history of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic (including cholecystectomy), and metabolic disease; and d) no clinically significant deviation for laboratory tests results.

Additional Inclusion Criteria for Participants with Hepatic Impairment Only:

  • Documented parenchymal hepatic disease evidenced by, e.g., ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), Fibroscan, or
  • Chronic (≥6 months) hepatic impairment (of any etiology) that has been clinically stable for at least 1 month prior to Screening as determined by the Principal Investigator (PI). Participants must also remain stable throughout the screening period
  • Has hepatic impairment as assessed by a classification score: Mild (5-6 points) or Moderate (7-9 points) according to hepatic function group
  • Has normal or non-clinically significant findings at physical examination and normal limits or non-clinically significant deviations in clinical laboratory evaluations with the exception of findings that in the opinion of the PI are consistent with participant's hepatic impairment or other stable chronic medical condition
  • Has a stable drug regimen for 14 days prior to study drug administration. Medications are allowed if they are essential for the management of hepatic impairment and the treatment of concomitant stable medical conditions for the hepatically impaired participants.

Exclusion criteria

Exclusion Criteria:

  • illness or surgery within 4 weeks prior to dosing
  • Gastrointestinal surgery that interferes with physiological absorption and motility (e.g. gastric bypass, duodenectomy) or gastric bands
  • Clinically significant history or presence of any gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting) that can interfere with drug absorption
  • History of suicidal tendency, disposition to seizures, state of confusion, or clinically relevant psychiatric diseases
  • Has any medical condition that could be aggravated by antagonism, such as disease or rheumatic disease
  • Has clinically significant or vital sign abnormalities at Screening
  • Has acute viral hepatitis in the 6 calendar months before the administration of the study drug
  • Has Gilbert's syndrome, an inherited (genetic) liver disorder that affects the body's ability to process
  • Has uncontrolled hyperlipidemia (abnormally high levels of lipids in the blood), which include cholesterol and triglycerides) as judged by the PI
  • History of significant drug abuse within 1 year prior to Screening or recreational use of soft drugs (such as marijuana) within 1 month, or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to Screening, unless for hepatic impaired participants only, the participant uses any of these drugs as prescriptions
  • History of significant alcohol abuse within 6 months prior to Screening or regular use of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol])
  • Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at Screening or menses) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing
  • Female participants with a positive pregnancy test at Screening or Day -1
  • Has a positive alcohol (breath or urine) test at Screening or Day -1
  • Has a history of clinically significant to dazucorilant, other related drugs, or any of the ingredients or of the study drug
  • Previous participation in a study with dazucorilant administration
  • Participated in a clinical research study involving the administration of an or marketed drug or device within 30 days prior to dosing, administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device
  • Participants who have taken a) oral, parenteral, depot or intra-articular glucocorticoids within 12 calendar months prior to study drug administration or b) intranasal, topical, or inhaled glucocorticoids within 2 weeks (or 5 half-lives, if longer) prior to study drug administration
  • Use of any drugs, herbal products, or other substances known to induce or inhibit hepatic drug metabolism (including St. John's wort) within 30 days prior to study drug administration
  • Male participants (including men who have had a vasectomy) with a pregnant or lactating partner
  • Breast-feeding female participants
  • Has inability or difficulty to swallow soft gelatin capsules
  • Has inability to be venipunctured and/or tolerate catheter venous access
  • Is an employee or family member of a contract research organization or Sponsor
  • Any reason which, in the opinion of the PI, would prevent the participant from participating in the study.

Additional Exclusion Criteria for Healthy Control Group Participants Only:

  • Has previously documented parenchymal hepatic disease evidenced by, for example, ultrasonography, CT, MRI, or . There is no requirement that control group participants have previously undergone any of these investigations, but results of any that have been performed must be negative
  • Has any clinically significant abnormality at physical examination, clinically significant abnormal laboratory test results, or positive test for surface antigen, virus (HCV), or (HIV) at Screening
  • Participants using medication other than topical products without significant systemic absorption: a) prescription medication within 14 days prior to the administration of study drug, b) over-the-counter (OTC) products and natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily), and c) a depot injection or an implant of any drug within 3 months prior to the administration of study drug
  • Participants with a positive urine drug screen at Screening or check-in.

Additional Exclusion Criteria for Participants with Hepatic Impairment Only:

  • Has clinically significant unstable medical conditions or clinically significant acute exacerbation of hepatic disease within 30 days of study drug administration in the opinion of the PI
  • Has clinically significant abnormalities of laboratory, ECG, or clinical data that would preclude participation in the study in the opinion of the PI
  • Has presence of chronic kidney disease
  • Has presence of hepatocellular carcinoma or acute hepatic disease from infection or drug toxicity
  • Has presence of clinically significant history of lactic acidosis and severe hepatomegaly with steatosis
  • Has presence of active stage 2, 3, or stage 4 hepatic encephalopathy
  • Has evidence of severe ascites at PI's discretion
  • Has Type 1 or uncontrolled Type 2 diabetes (decompensated diabetes, HbA1c >10 %)
  • Has presence of surgically-created or transjugular intrahepatic portal systemic shunts
  • Has a positive test for HIV
  • Has a positive drug screen at Screening or check-in. Participants who have a positive drug screen due to prescription drug use will be allowed if approved by the PI
  • Use of prohibited concomitant medication. At the discretion of the PI and Medical Monitor and with agreement of the participant's usual physician if applicable, a suitable substitute medication may be prescribed to replace the prohibited medication
  • Has history or clinical evidence of hepatic decompensation
  • Has history of liver transplant, or current placement on a liver transplant list
  • Use of medications for the timeframes specified below, with the exception of medications exempted by the PI on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or participant safety: a) prescription medications from 14 days prior to dosing (exceptions apply), or b) OTC and natural health products from 7 days prior to dosing unless a hepatic participant is taking such products for their routine care, with the exception of the occasional use of acetaminophen.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Moderate Hepatic Impairment

    On Day 1, each participant with moderate hepatic impairment will receive a single oral dose of dazucorilant 300 mg.

    Drug: Dazucorilant

  • Experimental
    Matched Healthy Participants

    Healthy participants will be matched to those with moderate hepatic impairment as to gender, age (± 10 years of the mean), and weight (± 20% of the mean). On Day 1, each healthy participant will receive a single oral dose of dazucorilant 300 mg.

    Drug: Dazucorilant

  • Experimental
    Mild Hepatic Impairment

    On Day 1, each participant with mild hepatic impairment will receive a single oral dose of dazucorilant 300 mg. This arm may be enrolled after review of interim PK evaluation of the effects of moderate hepatic impairment.

    Drug: Dazucorilant

Interventions

  • Dazucorilant 300 mg (4 X 75 mg) soft gelatin capsules for oral administration

    Also known as: CORT113176

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time zero to the last non-zero concentration (AUC0-t) of dazucorilant

    Time frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing

  2. Area under the concentration-time curve from time zero to infinity (extrapolated) (AUC0-inf) of dazucorilant

    Time frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing

  3. Maximum observed concentration (Cmax) of dazucorilant

    Time frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing

  4. Time to maximum concentration (Tmax) of dazucorilant

    Time frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing

  5. Apparent clearance (Cl/F) of dazucorilant

    Time frame: Predose and at serial timepoints up to 24 hours after dosing, and at 48, 72, 96, 120, and 144 hours after dosing

Secondary outcomes

  1. Number of participants with 1 or more adverse events

    Time frame: Up to Day 7

  2. Number of participants with 1 or more clinically significant abnormal vital signs

    Time frame: Up to Day 7

  3. Number of participants with 1 or more clinically significant abnormal electrocardiogram (ECG) result

    Time frame: Up to Day 7

  4. Number of participants with 1 or more clinically significant abnormal clinical laboratory result

    Time frame: Up to Day 7

  5. Number of participants with 1 or more clinically significant abnormal physical examination result

    Time frame: Up to Day 7

07

Study locations

2 sites
  • Site 2
    Rialto, California 92377, United States
  • Site 1
    Miami, Florida 33014, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Dec 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Apr 15, 2025
StartActual
Oct 8, 2024
Primary completionActual
Dec 9, 2024
CompletionActual
Dec 9, 2024
Last update
Apr 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06928779
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Oct 8, 2024
Primary completion
Dec 9, 2024
Completion
Dec 9, 2024
Last update
Apr 15, 2025

Study contacts

Jeevan Kunta, PhD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT113176

Start the discussion